Navigation Links
Panmira and FLAP LLCs Spun Out of Amira Pharmaceuticals
Date:9/8/2011

SAN DIEGO, Sept. 8, 2011 /PRNewswire/ -- Panmira Pharmaceuticals, LLC and FLAP, LLC, today announced their formation around certain assets spun out immediately preceding the acquisition of Amira Pharmaceuticals, Inc. (Amira) by Bristol-Myers Squibb Company (NYSE: BMY).  Panmira Pharmaceuticals received a number of assets, including Amira's DP2 antagonists, AM211 and AM461, both of which have successfully completed Phase I clinical studies.  FLAP, LLC is a non-operating company with rights to future milestones and royalties from Amira's 2008 licensing deal with GlaxoSmithKline related to the 5-lipoxygenase-activating protein (FLAP) inhibitor program.

"Now that we have successfully completed the sale of Amira to Bristol-Myers Squibb Company, a subset of the former Amira team will focus on completing our partnership efforts for the DP2 program," said Bob Baltera, Chief Executive Officer of Panmira Pharmaceuticals.  "We believe that spinning out these assets will be the best way to maximize their value for Amira's shareholders, and we look forward to accomplishing this goal."

Hari Kumar, Ph.D., Chief Business Officer, added, "Clinical trial results have demonstrated a dose proportional pharmacodynamic (PD) effect and good safety profiles for both AM211 and AM461.  These compounds are primed and ready for Phase II exploration in a number of clinical settings, including asthma, chronic obstructive pulmonary disease (COPD) and eosinophillic esophagitis.  We look forward to having the right partner to help make these plans come to fruition."

While there are no DP2 selective antagonists approved for therapeutic use, there is a strong scientific rationale for the target to be a novel, potentially disease-modifying treatment of asthma, COPD and allergic rhinitis. DP2, also known as chemoattractant receptor-homologous molecule expressed in Th2 lymphocytes (CRTH2), is a high affinity receptor for the prostaglandin D2 and is impli
'/>"/>

SOURCE Panmira Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals to Present Preclinical Data on AM152 , an LPA1 Receptor Antagonist, at the Annual Meeting of the American Thoracic Society
2. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
3. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
4. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
5. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
6. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
7. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
8. Visage Imaging Releases Amira 5.3
9. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
10. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
11. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Calif. , May 28, 2015 Today, ... to check a state prescription database before prescribing the ... and thousands of overdose deaths. SB 482, ... Bell Gardens , will require prescribers to check ... before prescribing Schedule II and III drugs, like OxyContin ...
(Date:5/28/2015)... , May 28, 2015 National Community Pharmacists ... MBA issued the following statement in response to a ... Policy Institute documenting that a number of generic drug ... report tracks with concerns previously expressed by NCPA and ... patient access to essential medications. Moreover, a 2015 survey ...
(Date:5/28/2015)... INDIANAPOLIS , May 28, 2015   Eli Lilly ... INCY ) will host a webcast on June 11 ... studies of baricitinib in rheumatoid arthritis. Data from these two trials, ... the Scientific Programme for the EULAR Congress 2015 in ... be held from 10:00 to11:00 a.m. Eastern Daylight Time. The ...
Breaking Medicine Technology:California Senate Approves Legislation Requiring Physicians To Check State Database Before Prescribing Powerful, Addictive Medications, Says Consumer Watchdog 2NCPA: AARP Drug Pricing Report Reiterates Need for Fair Generic Drug Reimbursements 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 3
... LONDON and CRANBURY, N.J., Oct. 29 GlaxoSmithKline PLC ... today announced a definitive agreement to develop and commercialize ... for the treatment of Fabry disease, a rare inherited ... receive an exclusive worldwide license to develop, manufacture and ...
... Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will ... be held November 10-12, 2010 at the Arizona Biltmore Hotel ... scheduled to present an overview of the Company and its ... 2010. To listen to the audio web cast ...
Cached Medicine Technology:GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease 2GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease 3GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease 4GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease 5GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease 6Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference 2Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference 3
(Date:5/28/2015)... AMVETS leaders this week congratulated AMVETS 2015 Memorial ... Newark, Del. AMVETS National Commander Larry Via personally called ... sweepstakes grand prize. , AMVETS selected the 10 lucky ... country for prizes ranging from $500 to the $10,000 ... at the AMVETS National Headquarters in Lanham, MD. , ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Are policies ... after a hospital stay triggering financial pain for seniors? ... American Journal of Managed Care set to figure out, ... recent federal rule change. , The study, “Observation Encounters ... A. Vashi, MD, MPH, examined how Medicare policies that ...
(Date:5/28/2015)... Florida (PRWEB) May 28, 2015 Ross ... plastic surgeon , has hired Teresa Beard as the ... In her role, Beard will oversee all marketing and ... years of experience leading teams and developing compelling marketing ... Face and Body Specialists, Beard served as guest communication ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Medelis, Inc., a ... has joined the company in the role of president. , ... leadership in the CRO industry,” said Larry Flanagan, Medelis’ CEO ... the company through our next phase of growth.” , ... its growth from nine employees to over 4,500 employees, achieving ...
(Date:5/28/2015)... As the summer approaches, many people will head to the ... safety a top priority, however, and that’s why Amica ... the Centers for Disease Control, 10 people die from drowning ... Additionally, the National Safety Council says drowning is the leading ... , Amica is sharing the following tips from the American ...
Breaking Medicine News(10 mins):Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:AJMC Study Examines Effect of Medicare Rules on Care After Hospital Observation 2Health News:AJMC Study Examines Effect of Medicare Rules on Care After Hospital Observation 3Health News:Clevens Face and Body Specialists Welcomes Teresa Beard as Marketing Director 2Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2Health News:Splash! Amica Shares 6 Swimming Safety Tips 2
... small amount in neck artery quadrupled the risk, study found ... even a small amount of plaque build-up in their carotid ... -- are up to four times more likely to suffer ... arteries, a new study finds. , "These results are important ...
... Idol,s Fight against Malaria, NEW YORK, March 19 ... airing Wednesday, April 9 (7:30-10:00 PM,ET/PT) on FOX, will raise ... year in a row as part of its star-studded event., ... named a beneficiary of Idol,Gives Back, which last year raised ...
... YORK, March 19 More than 90% of ... due to the lack of,effectiveness or adverse side ... could be avoided with pre-clinical tests using stem ... Information,s new report Stem Cells: Worldwide Markets for,Transplantation, ...
... QED International Associates Inc.,administrator for the HealthShares(TM) Indexes, a ... today announced the,quarterly rebalancing of the Indexes., The ... Indexes,effective before the opening of trading on NYSE Arca ... Drop GW Pharmaceuticals, Inc (LSE: GWP.L) ...
... March 19, 2008 The Russell Berrie Foundation has ... NewYork-Presbyterian Hospital, as part of a focused effort to ... concentrated research initiatives, toward a cure, the Medical Center ... killer, diabetes is a disease in which the bodys ...
... LAUSANNE, Switzerland, March 19 Galderma Pharma S.A., ... that its U.S. holding company, Galderma Laboratories, Inc., ... through the,expiration of the required waiting period under ... of CollaGenex,(Nasdaq: CGPI )., "We are ...
Cached Medicine News:Health News:Artery Plaque Boosts Hispanics' Odds for Stroke 2Health News:American Idol Spotlights Malaria Crisis During Idol Gives Back, April 9, On FOX 2Health News:Stem Cell Technology Offers Promise of Huge Savings for Drug Developers 2Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 2Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 3Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 4Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 5Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 6Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 7Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 8Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 9Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 10Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 11Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 12Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 13Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 14Health News:QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes 15Health News:Columbia University Medical Center/NYPH receive $28 million donation toward curing diabetes 2Health News:Columbia University Medical Center/NYPH receive $28 million donation toward curing diabetes 3Health News:Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 2Health News:Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 3Health News:Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 4Health News:Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 5
The Skull Pins are inserted into the receptacles of the Skull Clamp and fixate the head during surgery....
... designed for rigid skeletal fixation, ... freedom in positioning the fixation ... fixation is designed for the ... positions. Craniotomies can be performed ...
... rigid endoscopes for general applications and are equipped ... of borescopes, i.e. rigid endoscopes, range between 1 ... 0 up to a 120 retrospection, and image ... angle view. Endoscopes with working lengths of 1.5 ...
... Design for Neurosurgery. The Neuroview ... working channel scopes with a ... scope body facilitates a direct, ... The steerable tip allows access ...
Medicine Products: